Company intelligence / Profile preview

Medinol

Ownership: Private
Employees: ~300
Development stage: Commercial

Overview

Medinol’s EluNIR drug-eluting stent has received FDA approval and CE marking with excellent clinical outcomes. The company’s pipeline includes investigational devices such as ChampioNIR peripheral drug-eluting stent system (in First-in-Human trials), IoNIR and Xemed TAVR device for structural heart interventions. Microtech Sensors are in early human trials for monitoring atrial pressures in heart failure patients.

Therapeutic areas: Cardiovascular
Modalities: DeviceDrug-eluting stentImplantable microsensor
Industry: Implantable Medical Devices

Drug pipeline

1 asset

ridaforolimus

Commercial

Indications: Coronary artery disease

Partnerships

Not specifically disclosed.

Beyond the preview

Go deeper on Medinol.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medinol.